Skip to main content

Drug Repurposing

Adora Life Science Names Dr. Clinton Morgan Chief Medical Officer

Franklin, Tennessee – September 19, 2026 -- Adora Life Science has appointed Dr. Clinton D. Morgan, MD, as its full-time Chief Medical Officer, effective November 1, 2026, the company announced.

Neurosurgeon exits clinical practice to lead human trials for veterinary-derived drug

Dr. Morgan previously served on Adora's Board of Directors and consulted part-time on the company's human therapeutic strategy. In his new role, he will direct Adora's human clinical development, regulatory strategy, and scientific research network, and will chair a newly assembled Scientific Advisory Board spanning glycobiology, osteoarthritis, and radiation injury experts.